Global Deep Vein Thrombosis (DVT) Treatment Market, By Drugs Class (Anticoagulants, Heparin, Others), Treatment (Surgery, Drugs, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others) - Industry Trends and Forecast to 2030.
Deep Vein Thrombosis (DVT) Treatment Market Analysis and Size
The Global Deep Vein Thrombosis (DVT) Treatment Market is rising steadily as a result of the increasing incidence of deep vein thrombosis. Growing R&D activities is considerably driving the global deep vein thrombosis (DVT) treatment market. Strategic initiatives by the key market players are one of the elements driving the market's rapid rise. Market players are expanding their product offerings in order to acquire a competitive advantage.
Data Bridge Market Research analyses that the global deep vein thrombosis (DVT) treatment market which was USD 627.43 in 2022, would rocket up to USD 1,394.36 Million by 2030, and is expected to undergo a CAGR of 9.5% during the forecast period. This indicates the market value. “Anticoagulants” dominates the drugs class segment of the Global Deep Vein Thrombosis (DVT) Treatment Market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Deep Vein Thrombosis (DVT) Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs Class (Anticoagulants, Heparin, Others), Treatment (Surgery, Drugs, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa
|
|
Market Players Covered
|
Aspen Holdings (South Africa), Novartis AG (Germany), Mylan N.V. (U.S.), Momenta Pharmaceuticals, Inc. (U.S.), Hikma Pharmaceuticals PLC (UK), Laboratorios FarmaceuticosRovi, S.A. (Spain), GL Pharma (Austria), Cobapharma (Barcelona), BoehringerIngelheim GmbH (Germany), Glenmark Pharmaceuticals Inc.(India), Bristol-Myers Squibb Company (U.S.), Portola Pharmaceuticals, Inc.(U.S.) Daiichi Sankyo Company, Limited (Japan), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Bausch Health (Canada), VasudhaPharma (India), Tianyu Pharmaceutical Co., Ltd.(China), Neuland Laboratories Ltd (India), and Mitsubishi Tanabe Pharma Corporation (Japan)
|
|
Market Opportunities
|
|
Market Definition
The deep vein thrombosis (DVT) treatment refers to the market for products and therapies used in the diagnosis, prevention, and treatment of deep vein thrombosis—a medical condition characterized by the formation of blood clots in deep veins, typically in the legs. DVT can lead to serious complications, such as pulmonary embolism if not promptly diagnosed and treated. The market encompasses a wide range of treatment options, including medications (such as anticoagulants), medical devices (such as compression stockings, filters, and catheters), surgical interventions, and non-invasive procedures. It also includes diagnostic tools and tests used for the early detection and monitoring of DVT. The market is driven by factors such as the increasing prevalence of risk factors, advancements in diagnosis and treatment technologies, and growing awareness among healthcare professionals and the general population about the importance of early detection and timely management of DVT.
Global Deep Vein Thrombosis (DVT) Treatment Market Dynamics
Drivers
Increasing Incidence of Deep Vein Thrombosis
The incidence of deep vein thrombosis is rising globally due to factors such as sedentary lifestyles, obesity, the aging population, and the prevalence of risk factors like smoking and diabetes. This drives the demand for DVT treatment options.
Growing Awareness and Early Diagnosis
There is an increasing awareness of the signs, symptoms, and risks associated with DVT among healthcare professionals and the general population. Early diagnosis and timely treatment can prevent complications and improve patient outcomes, leading to a higher demand for DVT treatment.
Opportunities
Product Innovations and Pipeline Developments
There is a continuous focus on developing new and improved treatment options for DVT. Companies are investing in research and development to introduce innovative drugs, medical devices, and therapies that provide better efficacy, safety, and patient convenience.
Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising number of market players will further expand the market's growth rate in the future.
Restraints/Challenges
On the other hand, the high cost associated with product manufacturing is expected to obstruct market growth. Also, the disruption in the supply chain industry has the potential to challenge the market’s growth. Also, the lack of favorable reimbursement scenarios and technology penetration in the developing economies, and lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.
This global deep vein thrombosis (DVT) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global deep vein thrombosis (DVT) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2021, FDA approved first oral blood thinner, called Pradaxa (dabigatran etexilate) to treat children of age 3 months to 12 years with DVT.
Global Deep Vein Thrombosis (DVT) Treatment Market Scope
The global deep vein thrombosis (DVT) treatment market is segmented on the basis of drugs class, treatment, mode of administration, distribution channel, and end-user. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs Class
- Anticoagulants
- Heparin
- Others
Treatment
- Surgery
- Drugs
- Others
Mode Of Administration
- Injectable
- Oral
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End-User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Global Deep Vein Thrombosis (DVT) Treatment Market Regional Analysis/Insights
Global Deep Vein Thrombosis (DVT) Treatment Market is analyzed, and market size insights and trends are provided by drugs class, treatment, mode of administration, distribution channel, and end-user as referenced above.
The countries covered in the Global Deep Vein Thrombosis (DVT) Treatment Market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.
North America dominates the market due to factors including rising healthcare costs, increased R & D related to deep vein thrombosis treatment, and trending technological advancements.
Asia-Pacific is expected to witness the fastest growth during the forecast period of 2023 to 2030 because of the rising strategic initiatives by the key market players and favourable government initiatives in the region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and the challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global deep vein thrombosis (DVT) treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for the global deep vein thrombosis (DVT) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global deep vein thrombosis (DVT) treatment market. The data is available for the historic period 2015-2020.
Competitive Landscape and Deep Vein Thrombosis (DVT) Treatment Market Share Analysis
The global deep vein thrombosis (DVT) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global deep vein thrombosis (DVT) treatment market.
Some of the major players operating in the global deep vein thrombosis (DVT) treatment market are:
- Aspen Holdings (South Africa)
- Novartis AG (Germany)
- Mylan N.V. (U.S.)
- Momenta Pharmaceuticals, Inc. (U.S.)
- Hikma Pharmaceuticals PLC (UK)
- Laboratorios FarmaceuticosRovi, S.A. (Spain)
- GL Pharma (Austria)
- Cobapharma (Barcelona)
- BoehringerIngelheim GmbH (Germany)
- Glenmark Pharmaceuticals Inc.(India)
- Bristol-Myers Squibb Company (U.S.)
- Portola Pharmaceuticals, Inc.(U.S.)
- Daiichi Sankyo Company, Limited (Japan)
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG (Germany)
- Bausch Health (Canada)
- VasudhaPharma (India)
- Tianyu Pharmaceutical Co., Ltd.(China)
- Neuland Laboratories Ltd (India)
- Mitsubishi Tanabe Pharma Corporation (Japan)
SKU-